2 research outputs found
The Human Cell Atlas White Paper
The Human Cell Atlas (HCA) will be made up of comprehensive reference maps of
all human cells - the fundamental units of life - as a basis for understanding
fundamental human biological processes and diagnosing, monitoring, and treating
disease. It will help scientists understand how genetic variants impact disease
risk, define drug toxicities, discover better therapies, and advance
regenerative medicine. A resource of such ambition and scale should be built in
stages, increasing in size, breadth, and resolution as technologies develop and
understanding deepens. We will therefore pursue Phase 1 as a suite of flagship
projects in key tissues, systems, and organs. We will bring together experts in
biology, medicine, genomics, technology development and computation (including
data analysis, software engineering, and visualization). We will also need
standardized experimental and computational methods that will allow us to
compare diverse cell and tissue types - and samples across human communities -
in consistent ways, ensuring that the resulting resource is truly global.
This document, the first version of the HCA White Paper, was written by
experts in the field with feedback and suggestions from the HCA community,
gathered during recent international meetings. The White Paper, released at the
close of this yearlong planning process, will be a living document that evolves
as the HCA community provides additional feedback, as technological and
computational advances are made, and as lessons are learned during the
construction of the atlas
Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma
Background/Aims: The human Anterior
Gradient-2 (AGR2) is strongly upregulated in various
human cancers, including pancreatic ductal
adenocarcinomas (PDAC), but its prognostic value in
PDAC has not yet been studied. Methods: We analysed
19 microdissected PDAC cases at the mRNA level, and
also 148 cases at the protein level by immunohistochemistry based on tissue microarray, using a
monoclonal AGR2 antibody, and statistical analyses
were applied to test for prognostic associations. Results:
Overexpression of AGR2 mRNA was found to be
elevated in most pancreatic cell lines and in
microdissected pancreatic cancer compared to
microdissected normal ductal cells. AGR2 protein was
expressed in 109/148 (73.7%) of PDAC, with a higher
expression in female patients (p=0.040), whereas no
significant associations with other clinical-pathological
parameters were found. A prognostic value of AGR2
could not be demonstrated in univariate analyses.
Conclusion: Although a prognostic value of AGR2
seems unlikely, further studies are warranted to
investigate the biological role of AGR2 in pancreatic
adenocarcinomas